Literature DB >> 26186265

Chloride dysregulation and inhibitory receptor blockade yield equivalent disinhibition of spinal neurons yet are differentially reversed by carbonic anhydrase blockade.

Kwan Yeop Lee1, Steven A Prescott.   

Abstract

Synaptic inhibition plays a key role in processing somatosensory information. Blocking inhibition at the spinal level is sufficient to produce mechanical allodynia, and many neuropathic pain conditions are associated with reduced inhibition. Disinhibition of spinal neurons can arise through decreased GABAA/glycine receptor activation or through dysregulation of intracellular chloride. We hypothesized that these distinct disinhibitory mechanisms, despite all causing allodynia, are differentially susceptible to therapeutic intervention. Specifically, we predicted that reducing bicarbonate efflux by blocking carbonic anhydrase with acetazolamide (ACTZ) would counteract disinhibition caused by chloride dysregulation without affecting normal inhibition or disinhibition caused by GABAA/glycine receptor blockade. To test this, responses to innocuous tactile stimulation were recorded in vivo from rat superficial dorsal horn neurons before and after different forms of pharmacological disinhibition and again after application of ACTZ. Blocking GABAA or glycine receptors caused hyperresponsiveness equivalent to that caused by blocking the potassium chloride cotransporter KCC2, but, consistent with our predictions, only disinhibition caused by KCC2 blockade was counteracted by ACTZ. ACTZ did not alter responses of neurons with intact inhibition. As pathological downregulation of KCC2 is triggered by brain-derived neurotrophic factor, we also confirmed that ACTZ was effective against brain-derived neurotrophic factor-induced hyperresponsiveness. Our results argue that intrathecal ACTZ has antiallodynic effects only if allodynia arises through chloride dysregulation; therefore, behavioral evidence that ACTZ is antiallodynic in nerve-injured animals affirms the contribution of chloride dysregulation as a key pathological mechanism. Although different disinhibitory mechanisms are not mutually exclusive, these results demonstrate that their relative contribution dictates which specific therapies will be effective.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26186265     DOI: 10.1097/j.pain.0000000000000301

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  11 in total

1.  Hypoxia-induced carbonic anhydrase mediated dorsal horn neuron activation and induction of neuropathic pain.

Authors:  Marlene E Da Vitoria Lobo; Nick Weir; Lydia Hardowar; Yara Al Ojaimi; Ryan Madden; Alex Gibson; Samuel M Bestall; Masanori Hirashima; Chris B Schaffer; Lucy F Donaldson; David O Bates; Richard Philip Hulse
Journal:  Pain       Date:  2022-03-29       Impact factor: 7.926

2.  The MNK-eIF4E Signaling Axis Contributes to Injury-Induced Nociceptive Plasticity and the Development of Chronic Pain.

Authors:  Jamie K Moy; Arkady Khoutorsky; Marina N Asiedu; Bryan J Black; Jasper L Kuhn; Paulino Barragán-Iglesias; Salim Megat; Michael D Burton; Carolina C Burgos-Vega; Ohannes K Melemedjian; Scott Boitano; Josef Vagner; Christos G Gkogkas; Joseph J Pancrazio; Jeffrey S Mogil; Gregory Dussor; Nahum Sonenberg; Theodore J Price
Journal:  J Neurosci       Date:  2017-07-03       Impact factor: 6.167

Review 3.  Purinergic signalling in spinal pain processing.

Authors:  Theresa H Tam; Michael W Salter
Journal:  Purinergic Signal       Date:  2020-11-10       Impact factor: 3.765

4.  Neuroligin 2 regulates spinal GABAergic plasticity in hyperalgesic priming, a model of the transition from acute to chronic pain.

Authors:  Ji-Young V Kim; Salim Megat; Jamie K Moy; Marina N Asiedu; Galo L Mejia; Josef Vagner; Theodore J Price
Journal:  Pain       Date:  2016-06       Impact factor: 7.926

5.  Loss of STEP61 couples disinhibition to N-methyl-d-aspartate receptor potentiation in rodent and human spinal pain processing.

Authors:  Annemarie Dedek; Jian Xu; Chaya M Kandegedara; Louis-Étienne Lorenzo; Antoine G Godin; Yves De Koninck; Paul J Lombroso; Eve C Tsai; Michael E Hildebrand
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

6.  Remifentanil-Induced Secondary Hyperalgesia Is Not Prevented By Preoperative Acetazolamide Administration In Patients Undergoing Total Thyroidectomy: A Randomized Controlled Trial.

Authors:  Rodrigo Gutiérrez; Felipe Contreras; Alonso Blanch; Daniela Bravo; José I Egaña; Daniel Rappoport; Patricio Cabané; Francisco Rodríguez; Antonello Penna
Journal:  J Pain Res       Date:  2019-11-06       Impact factor: 3.133

7.  Excitatory neurons are more disinhibited than inhibitory neurons by chloride dysregulation in the spinal dorsal horn.

Authors:  Kwan Yeop Lee; Stéphanie Ratté; Steven A Prescott
Journal:  Elife       Date:  2019-11-19       Impact factor: 8.140

8.  Carbonic Anhydrase IV Selective Inhibitors Counteract the Development of Colitis-Associated Visceral Pain in Rats.

Authors:  Elena Lucarini; Alessio Nocentini; Alessandro Bonardi; Niccolò Chiaramonte; Carmen Parisio; Laura Micheli; Alessandra Toti; Valentina Ferrara; Donatello Carrino; Alessandra Pacini; Maria Novella Romanelli; Claudiu T Supuran; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Cells       Date:  2021-09-26       Impact factor: 6.600

9.  Microglial pannexin-1 channel activation is a spinal determinant of joint pain.

Authors:  Michael Mousseau; Nicole E Burma; Kwan Yeop Lee; Heather Leduc-Pessah; Charlie H T Kwok; Allison R Reid; Melissa O'Brien; Boriss Sagalajev; Jo Anne Stratton; Natalya Patrick; Patrick L Stemkowski; Jeff Biernaskie; Gerald W Zamponi; Paul Salo; Jason J McDougall; Steven A Prescott; John R Matyas; Tuan Trang
Journal:  Sci Adv       Date:  2018-08-08       Impact factor: 14.136

10.  Differential Modulation of Dorsal Horn Neurons by Various Spinal Cord Stimulation Strategies.

Authors:  Kwan Yeop Lee; Dongchul Lee; Zachary B Kagan; Dong Wang; Kerry Bradley
Journal:  Biomedicines       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.